-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on Summit Therapeutics, Lowers Price Target to $23

Benzinga·05/04/2026 10:53:49
Listen to the news
HC Wainwright & Co. analyst Mitchell S. Kapoor maintains Summit Therapeutics (NASDAQ:SMMT) with a Buy and lowers the price target from $30 to $23.